- Latest available (Revised)
- Point in Time (31/12/2020)
- Original (As adopted by EU)
Commission Regulation (EU) No 1017/2013 of 23 October 2013 refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to children’s development and health (Text with EEA relevance)
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
Point in time view as at 31/12/2020.
There are currently no known outstanding effects for the Commission Regulation (EU) No 1017/2013, ANNEX.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
Application – Relevant provisions of Regulation (EC) No 1924/2006 | Nutrient, substance, food or food category | Claim | EFSA opinion reference |
---|---|---|---|
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data | ‘Hypo-caloric snacks (KOT products)’ | Contributes to reduce the adipocytes size at the abdominal level, in the context of a low-calorie diet | Q-2011-00016 |
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data | Isoleucyl-prolyl-proline (IPP) and valyl-prolyl-proline (VPP) | Peptides IPP and VPP help to maintain normal blood pressure | Q-2011-00121 |
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data | Appl’In® polyphenolic apple extract powder (Malus domestica) | Appl’In® contributes to decrease glycaemic response in women | Q-2011-00190 |
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data | Coffee C21 | Regular consumption of Coffee C21 contributes to the maintenance of DNA integrity in cells of the body | Q-2011-00783 |
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data | Diacylglycerol (DAG) oil | Substituting your usual vegetable oil with DAG oil helps in the management of body weight through weight loss | Q-2011-00751 |
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data | Spermidine | Spermidine prolongs the growing phase (anagen) of the hair cycle | Q-2011-00896 |
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data | Bimuno® (Bimuno® GOS) | Regular daily consumption of 1,37 g galacto-oligosaccharides from Bimuno® may reduce intestinal discomfort | Q-2011-00401 |
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data | Sugar beet fibre | Sugar beet fibre decreases intestinal transit time | Q-2011-00971 |
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: